id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-348310-nc1tq5af	Vázquez-Ramírez, Daniel	High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system	2019-02-23		.txt	text/plain	7472	232	41	Modified Vaccinia Virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases Viral vaccine production in cell culture Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines The avian EB66® cell line, application to vaccines, and therapeutic protein production The development and manufacture of influenza vaccines Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line Phase I clinical trial safety of DNA-and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers Very high density of CHO cells in perfusionby ATF or TFF in WAVE bioreactor™-Part I. Effect of the cell density on the process Preparation of cell cultures and vaccinia virus stocks Use of cell bleed in a high cell density perfusion culture and multivariable control of biomass and metabolite concentrations High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells Clinical development of modified vaccinia virus Ankara vaccines Current status for high titre poxvirus stock preparation in CEF under serumfree medium conditions: implication for vaccine development Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis MVA and NYVAC as vaccines against emergent infectious diseases and cancer Poxvirus vectors as HIV/AIDS vaccines in humans. The latter differed Similarly, the volumetric productivity (P V ) was calculated considering vir T , the total spent medium during cell growth and virus replication phase (V T, L), and the total process time (t T, day), by: Samples of 6-8 mL from bioreactor cultures were taken with a syringe through a Luer-Lock-septum in 12 or 24-h intervals and stored at − 80°C until analysis.	cache/cord-348310-nc1tq5af.txt	txt/cord-348310-nc1tq5af.txt
